Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
25ste Nationale Longkanker Symposium
feb 2024 | Chirurgie, Immuuntherapie, Longoncologie, Radiotherapie